Determination of the enantioselectivity of six chiral aryloxy aminopropanol drugs transport across Caco-2 cell monolayers

Masubuchi, 1993, Substrate stereoselectivity and enantiomer/enantiomer interaction in propranolol metabolism in rat liver microsomes, Biochem Pharmacol, 46, 1759, 10.1016/0006-2952(93)90580-P Zhou, 2001, Chiral metabolism of propafenone in rat hepatic microsomes treated with induers, World J Gastroenterol, 7, 830, 10.3748/wjg.v7.i6.830 Yu, 2010, Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9, Chirality, 22, 456 Tang, 2004, Stereoselective RP-HPLC determination of esmolol enantiomers in human plasma after pre-column derivatization, J Biochem Biophys Methods, 59, 159, 10.1016/j.jbbm.2003.12.006 Schlauch, 2002, Enantioselective determination of (R)- and (S)-sotalol in human plasma by on-line coupling of a restricted-access material precolumn to a cellobiohydrolase I-based chiral stationary phase, J Chromatogr B, 775, 197, 10.1016/S1570-0232(02)00287-8 He, 2010, Reversed-phase high-performance liquid chromatographic analysis of seven pairs of chiral drug enantiomers in transport medium after chiral derivatization, J Chin Pharm Sci, 19, 104, 10.5246/jcps.2010.02.014 Yamaguchi, 2001, Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2, Eur J Pharmacol, 431, 297, 10.1016/S0014-2999(01)01448-0 Hu, 2004, Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 culture model, Mol Pharmacol, 1, 194, 10.1021/mp034012d Walgren, 1998, Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cell, Biochem Pharmacol, 55, 1721, 10.1016/S0006-2952(98)00048-3 Lee, 2002, Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers, J Pharmacol Exp Ther, 303, 574, 10.1124/jpet.102.038521 Naruhashi, 2003, Experimental demonstration of the unstirred water layer effect on drug transport in Caco-2 cells, J Pharm Sci, 92, 1502, 10.1002/jps.10409 Krishna, 2001, Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2, Inter J Pharm, 222, 77, 10.1016/S0378-5173(01)00698-6 Bachmakov, 2006, Characterization of beta-adrenoceptorant agonists as substrates and inhibitors of the drug transporter P-glycoprotein., Fundam Clin Pharmacol, 20, 273, 10.1111/j.1472-8206.2006.00408.x Kuo, 1994, The contribution of intestinal secretion to the dose-dependent absorption of celiprolol, Pharm Res, 11, 648, 10.1023/A:1018959809352 Karlsson, 1993, Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein, Br J Pharmacol, 110, 1009, 10.1111/j.1476-5381.1993.tb13914.x Bansal, 2007, Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies, J Chromatogr B, 859, 261, 10.1016/j.jchromb.2007.09.025 Watkins, 1997, The barrier function of CYP3A4 and P-glycoprotein in the small bowel, Adv Drug Deliv Rev, 27, 161, 10.1016/S0169-409X(97)00041-0 Mallants, 2009, An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency, J Pharm Pharmacol, 61, 883, 10.1211/jpp.61.07.0007 Prieto, 2010, An exploratory study of two Caco-2 cell models for oral absorption: a report on their within-laboratory and between-laboratory variability, and their predictive capacity, Altern Lab Anim, 38, 367, 10.1177/026119291003800510 Yang, 2007, Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership, Mol Pharm, 4, 608, 10.1021/mp070028i Augustijns, 2004, HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model, Pharm Biomed Anal, 34, 971, 10.1016/j.jpba.2003.11.016 Bachmakov, 2005, Characterization of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein, Naunyn Schmiedebergs Arch Pharmacol, 371, 195, 10.1007/s00210-005-1025-y He, 2006, Determination of the stereoselectivity of chiral drug transport across Caco-2 cell monolayers, Chirality, 18, 64, 10.1002/chir.20218 Wang, 2010, Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers, Chirality, 22, 361 Jonsson, 1999, Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity, Biochem Pharmacol, 58, 1801, 10.1016/S0006-2952(99)00262-2 Tsuji, 1996, Carrier-mediated intestinal transport of drugs, Pharm Res, 13, 963, 10.1023/A:1016086003070 De Mey, 1990, Carvedilol increases the systemic bioavailability of oral digoxin, Br J Clin Pharmacol, 29, 486, 10.1111/j.1365-2125.1990.tb03668.x Ratnapalan, 2003, Digoxin-carvedilol interactions in children, J Pediatr, 142, 572, 10.1067/mpd.2003.160 Kakumoto, 2003, Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil, Cancer Sci, 94, 81, 10.1111/j.1349-7006.2003.tb01356.x